1. Diamond v. Chakrabarty (1980, U.S. Supreme Court)

This is the foundational biotechnology patent case.

Facts:

An Indian scientist, Ananda Chakrabarty, genetically engineered a bacterium capable of breaking down crude oil. He applied for a patent on the organism.

Legal Issue:

Can a living organism created through genetic engineering be patented?

Judgment:

The U.S. Supreme Court ruled YES, stating that:

“Anything under the sun that is made by man” can be patented.

Importance:

• Opened the door for biotech patents
• Distinguished between natural organisms and human-made genetic modifications
• Became the backbone for later gene and stem cell patent claims

Relevance to embryonic gene disputes:

It did NOT involve embryos directly, but it established that modified biological material can be patented—later extended to DNA and stem cells.

2. Association for Molecular Pathology v. Myriad Genetics (2013, U.S. Supreme Court)

This is the most important gene patent case.

Facts:

Myriad Genetics discovered the location and sequence of the BRCA1 and BRCA2 genes, linked to breast and ovarian cancer risk. It obtained patents on isolated DNA sequences and diagnostic testing.

Legal Issue:

Can isolated human genes be patented?

Judgment:

The Court ruled:

• Naturally occurring DNA cannot be patented
• BUT synthetically created DNA (cDNA) can be patented

Reasoning:

• Isolated genes are still “products of nature”
• Discovering a gene is not the same as inventing it

Importance:

• Invalidated thousands of gene patents
• Changed the biotech industry model (diagnostics became more open)
• Strongly limited ownership claims over human genetic material, including embryonic DNA sequences

3. Mayo Collaborative Services v. Prometheus (2012, U.S. Supreme Court)

Although not about embryos directly, this case reshaped all biotech patent law.

Facts:

Prometheus Laboratories held patents on methods for adjusting drug dosage based on metabolite levels in the body.

Legal Issue:

Can a natural biological correlation be patented as a medical method?

Judgment:

No. The patents were invalid.

Key Principle:

You cannot patent:

• Natural laws
• Natural correlations
• Basic biological relationships

Importance for embryonic gene disputes:

• Reinforced that natural biological processes cannot be monopolized
• Later used to challenge stem cell and gene-expression patents involving embryos

4. Wisconsin Alumni Research Foundation (WARF) Stem Cell Patents (U.S. litigation, 2006–2010s)

Facts:

Wisconsin Alumni Research Foundation held patents on human embryonic stem cells derived from blastocysts (early-stage embryos).

The patents covered:

• Methods to isolate embryonic stem cells
• Cell lines derived from human embryos

Legal Challenge:

Public interest groups argued:

• The patents were too broad
• Embryonic stem cells were not truly “invented”
• They violated patent eligibility rules

Outcome:

• Some claims were narrowed or invalidated during reexamination proceedings
• Others survived in modified form

Importance:

• First major legal confrontation over human embryonic stem cell ownership
• Highlighted ethical concerns: destruction of embryos during research
• Showed that process-based claims may survive even when biological material claims fail

5. Brüstle v. Greenpeace (2011, Court of Justice of the European Union)

This is the leading European embryonic stem cell case.

Facts:

Oliver Brüstle held a patent on neural precursor cells derived from human embryonic stem cells.

Legal Issue:

Can inventions involving human embryos be patented under EU law?

Judgment:

The Court ruled:

• Any invention requiring destruction of a human embryo is not patentable
• This includes stem cell derivation methods

Reasoning:

• Embryos have moral status under EU law
• Public policy prohibits commercialization of embryo destruction

Importance:

• Extremely restrictive compared to the U.S.
• Effectively bans most embryonic stem cell patents in Europe

6. In re ZymoGenetics / Recombinant DNA patent disputes (U.S. Federal Circuit cases, 2000s)

These cases involved recombinant proteins and gene fragments used in biomedical research.

Facts:

Companies like ZymoGenetics sought patents on proteins originally derived from human biological processes (including embryonic expression pathways).

Legal Issue:

Can naturally derived proteins or gene fragments be patented if isolated and purified?

Outcome:

Courts increasingly ruled:

• Purification alone is not enough for patentability
• The invention must involve markedly different characteristics from nature

Importance:

• Reinforced the “product of nature” doctrine
• Narrowed patent scope over biological materials derived from embryos or human tissue

Key Themes Across All Cases

1. Nature vs Invention

Courts consistently ask:

• Is this a discovery of something natural?
• Or a human-made invention?

2. Embryo Ethical Status

Especially in Europe:

• Embryos are given moral protection
• This limits patentability regardless of technical innovation

3. Shift in U.S. Law After 2012–2013

After:

• Mayo (2012)
• Myriad (2013)

The U.S. position became:

• Genes = not patentable if naturally occurring
• Modified genetic constructs = potentially patentable

4. Scientific Impact

These rulings:

• Reduced monopolies over genetic testing
• Increased open scientific research access
• Shifted biotech companies toward synthetic biology and engineered sequences

Conclusion

Embryonic gene patent disputes are not governed by a single rule but by a gradual tightening of what counts as “human invention” versus “natural biology.”

• U.S. law now draws a sharp line between natural DNA (not patentable) and synthetic modifications (patentable)
• Europe goes further, often excluding embryonic-derived inventions entirely on ethical grounds
• Early cases like Chakrabarty expanded biotech patents, while modern cases like Myriad and Mayo significantly restricted them